XML 40 R25.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2017 and 2016:

		December 31, 2017
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^® software patent		$	31,951			$	(8,487	)		$	23,464				11.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,293,614				(171,911	)			1,121,703				15
Hormone therapy drug candidate patents (pending)			1,721,305				—				1,721,305				n/a
Non-amortizable intangible assets:
Multiple trademarks			233,275				—				233,275				indefinite
TOTAL		$	3,371,888			$	(272,141	)		$	3,099,747

		December 31, 2016
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^® software patent		$	31,951			$	(6,490	)		$	25,461				12.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,093,452				(102,393	)			991,059				16
Hormone therapy drug candidate patents (pending)			1,203,987				—				1,203,987				n/a
Non-amortizable intangible assets:
Multiple trademarks for vitamins/supplements			185,465				—				185,465				indefinite
Total		$	2,606,598			$	(200,626	)		$	2,405,972

Schedule of estimated amortization expense

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Year Ending December 31,				Estimated Amortization
	2018			$	76,777
	2019			$	76,777
	2020			$	76,777
	2021			$	76,777
	2022			$	76,777
	Thereafter			$	761,282